O
OrbiMed’s Enliven Therapeutics ELVN Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $160M | Hold |
7,959,538
| – | – | 3.99% | 5 |
|
|
2025
Q1 | $157M | Hold |
7,959,538
| – | – | 3.73% | 5 |
|
|
2024
Q4 | $179M | Hold |
7,959,538
| – | – | 3.68% | 6 |
|
|
2024
Q3 | $203M | Hold |
7,959,538
| – | – | 3.69% | 6 |
|
|
2024
Q2 | $186M | Sell |
7,959,538
-1,038,800
| -12% | -$24.3M | 3.67% | 7 |
|
|
2024
Q1 | $158M | Hold |
8,998,338
| – | – | 2.9% | 9 |
|
|
2023
Q4 | $125M | Hold |
8,998,338
| – | – | 2.49% | 9 |
|
|
2023
Q3 | $123M | Hold |
8,998,338
| – | – | 2.61% | 7 |
|
|
2023
Q2 | $184M | Buy |
8,998,338
+2,125
| +0% | +$43.4K | 3.33% | 3 |
|
|
2023
Q1 | $197M | Buy |
8,996,213
+4,609,645
| +105% | +$101M | 3.87% | 2 |
|
|
2022
Q4 | $17.9M | Hold |
4,386,568
| – | – | 0.34% | 67 |
|
|
2022
Q3 | $10K | Hold |
4,386,568
| – | – | 0.19% | 85 |
|
|
2022
Q2 | $5.35K | Hold |
4,386,568
| – | – | 0.1% | 109 |
|
|
2022
Q1 | $8.25M | Hold |
4,386,568
| – | – | 0.13% | 105 |
|
|
2021
Q4 | $9.87M | Hold |
4,386,568
| – | – | 0.13% | 117 |
|
|
2021
Q3 | $17.9M | Buy |
4,386,568
+1,666,666
| +61% | +$6.8M | 0.2% | 103 |
|
|
2021
Q2 | $21.5M | Hold |
2,719,902
| – | – | 0.22% | 96 |
|
|
2021
Q1 | $23M | Hold |
2,719,902
| – | – | 0.21% | 91 |
|
|
2020
Q4 | $60M | Hold |
2,719,902
| – | – | 0.52% | 53 |
|
|
2020
Q3 | $55.3M | Hold |
2,719,902
| – | – | 0.7% | 42 |
|
|
2020
Q2 | $75.2M | Hold |
2,719,902
| – | – | 1.06% | 30 |
|
|
2020
Q1 | $43.6M | Buy |
+2,719,902
| New | +$43.6M | 0.73% | 43 |
|